Literature DB >> 34244607

PAX8 plays an essential antiapoptotic role in uterine serous papillary cancer.

Basem Fares1,2, Liron Berger2, Einav Bangiev-Girsh1,2, Reli Rachel Kakun1,2, Dima Ghannam-Shahbari1,2, Yuval Tabach3, Yaniv Zohar4, Eyal Gottlieb1, Ruth Perets5,6.   

Abstract

Endometrial carcinoma (EC) is the fourth-most common cancer in women in the United States, and generally carries a favorable prognosis. However, about 10% of EC patients have a rare and aggressive form, uterine serous papillary carcinoma (USPC), which carries a much higher mortality rate. The developmental transcription factor PAX8 is expressed in nearly 100% of USPCs. We show that PAX8 plays a critical antiapoptotic role in USPC and this role is established via transcriptional activation of two aberrant signaling pathways. First, PAX8 positively regulates mutated p53, and missense p53 mutations have an oncogenic gain of function effect. Second, PAX8 directly transcriptionally regulates p21, in a p53-independent manner, and p21 acquires a growth promoting role that is mediated via cytoplasmic localization of the protein. We propose that mutated p53 and cytoplasmic p21 can independently mediate the pro-proliferative role of PAX8 in USPC. In addition, we performed a genome-wide transcriptome analysis to detect pathways that are regulated by PAX8, and propose that metabolism and HIF-1alpha -related pathways are potential candidates for mediating the role of PAX8 in USPC. Taken together our findings demonstrate for the first time that PAX8 is an essential lineage marker in USPC, and suggest its mechanism of action.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Year:  2021        PMID: 34244607     DOI: 10.1038/s41388-021-01925-z

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  52 in total

1.  A candidate precursor to serous carcinoma that originates in the distal fallopian tube.

Authors:  Y Lee; A Miron; R Drapkin; M R Nucci; F Medeiros; A Saleemuddin; J Garber; C Birch; H Mou; R W Gordon; D W Cramer; F D McKeon; C P Crum
Journal:  J Pathol       Date:  2007-01       Impact factor: 7.996

2.  Serous EIC as an early form of uterine papillary serous carcinoma: recent progress in understanding its pathogenesis and current opinions regarding pathologic and clinical management.

Authors:  Wenxin Zheng; Peter E Schwartz
Journal:  Gynecol Oncol       Date:  2005-03       Impact factor: 5.482

3.  Bokhman Redux: Endometrial cancer "types" in the 21st century.

Authors:  Adrian A Suarez; Ashley S Felix; David E Cohn
Journal:  Gynecol Oncol       Date:  2016-12-16       Impact factor: 5.482

4.  BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma.

Authors:  Kathryn P Pennington; Tom Walsh; Ming Lee; Christopher Pennil; Akiva P Novetsky; Kathy J Agnew; Anne Thornton; Rochelle Garcia; David Mutch; Mary-Claire King; Paul Goodfellow; Elizabeth M Swisher
Journal:  Cancer       Date:  2012-07-18       Impact factor: 6.860

Review 5.  Molecular characterization of endometrial cancer and therapeutic implications.

Authors:  Boris Winterhoff; Lauren Thomaier; Sally Mullany; Matthew A Powell
Journal:  Curr Opin Obstet Gynecol       Date:  2020-02       Impact factor: 1.927

6.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

7.  Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation.

Authors:  R A Ambros; M E Sherman; C M Zahn; P Bitterman; R J Kurman
Journal:  Hum Pathol       Date:  1995-11       Impact factor: 3.466

Review 8.  Uterine papillary serous carcinoma: epidemiology, pathogenesis and management.

Authors:  Amanda Nickles Fader; David Boruta; Alexander B Olawaiye; Paola A Gehrig
Journal:  Curr Opin Obstet Gynecol       Date:  2010-02       Impact factor: 1.927

9.  Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial.

Authors:  Louise A Brinton; Ashley S Felix; D Scott McMeekin; William T Creasman; Mark E Sherman; David Mutch; David E Cohn; Joan L Walker; Richard G Moore; Levi S Downs; Robert A Soslow; Richard Zaino
Journal:  Gynecol Oncol       Date:  2013-02-26       Impact factor: 5.482

Review 10.  Endometrial carcinoma in situ in postmenopausal women.

Authors:  G W Spiegel
Journal:  Am J Surg Pathol       Date:  1995-04       Impact factor: 6.394

View more
  1 in total

Review 1.  PAX8 in the Junction between Development and Tumorigenesis.

Authors:  Reli Rachel Kakun; Zohar Melamed; Ruth Perets
Journal:  Int J Mol Sci       Date:  2022-07-03       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.